Cost analysis of allogeneic bone marrow transplantation

Abstract

The aim of this economic evaluation was to assess the costs of the first year of genotypically identical HLA allogeneic bone marrow transplantation (BMT) for the treatment of adults patients with acute myeloid leukemia (AML) in first complete remission (CR1). During the first year of follow-up the following were assessed 1) variable direct medical (VDM) cost (drugs, blood products, lab tests, radiological procedures, hospital days) and the part of this cost paid by the Besançon Hospital from it own budget 2) the total cost.

Ten consecutive patients from the Hematology Department of the Besançon University Hospital (France) transplanted from 1995 to 1996 for AML in CR1 were included in the analysis. This retrospective study was carried out using the French Health Care Insurance System (HCIS) perspective. Medical data were collected from the medical records of the patients. The overhead and logistics charges came from the analytic accounting report which was used to assess the mean cost of the first year of follow-up (in e and 1999 US$).

The variable medical cost for the first year of follow-up for an allogeneic BMT amounted to 66,186 e (US$ 70,542). Total direct cost for the first year of follow-up was 111,454 e (US$ 118,459) (82,963 e, US$ 88,422 for the first six months). 95% of that cost was paid by the State Hospital from it own budget.